CRVS
Price
$3.66
Change
-$0.00 (-0.00%)
Updated
Apr 25, 02:22 PM (EDT)
Capitalization
249.38M
6 days until earnings call
VKTX
Price
$24.93
Change
-$0.74 (-2.88%)
Updated
Apr 25, 03:56 PM (EDT)
Capitalization
2.88B
89 days until earnings call
Ad is loading...

CRVS vs VKTX

Header iconCRVS vs VKTX Comparison
Open Charts CRVS vs VKTXBanner chart's image
Corvus Pharmaceuticals
Price$3.66
Change-$0.00 (-0.00%)
Volume$600
Capitalization249.38M
Viking Therapeutics
Price$24.93
Change-$0.74 (-2.88%)
Volume$6.29K
Capitalization2.88B
CRVS vs VKTX Comparison Chart
Loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRVS vs. VKTX commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Buy and VKTX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (CRVS: $3.66 vs. VKTX: $25.66)
Brand notoriety: CRVS and VKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 187% vs. VKTX: 74%
Market capitalization -- CRVS: $249.38M vs. VKTX: $2.88B
CRVS [@Biotechnology] is valued at $249.38M. VKTX’s [@Biotechnology] market capitalization is $2.88B. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileVKTX’s FA Score has 0 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • VKTX’s FA Score: 0 green, 5 red.
According to our system of comparison, VKTX is a better buy in the long-term than CRVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 4 TA indicator(s) are bullish while VKTX’s TA Score has 5 bullish TA indicator(s).

  • CRVS’s TA Score: 4 bullish, 4 bearish.
  • VKTX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, VKTX is a better buy in the short-term than CRVS.

Price Growth

CRVS (@Biotechnology) experienced а +12.96% price change this week, while VKTX (@Biotechnology) price change was +7.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.17%. For the same industry, the average monthly price growth was -4.24%, and the average quarterly price growth was -12.55%.

Reported Earning Dates

CRVS is expected to report earnings on Aug 12, 2025.

VKTX is expected to report earnings on Jul 23, 2025.

Industries' Descriptions

@Biotechnology (+7.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VKTX($2.88B) has a higher market cap than CRVS($249M). CRVS YTD gains are higher at: -31.589 vs. VKTX (-36.233). CRVS has higher annual earnings (EBITDA): -25M vs. VKTX (-150.58M). VKTX has more cash in the bank: 903M vs. CRVS (41.7M). CRVS has less debt than VKTX: CRVS (354K) vs VKTX (1.12M). CRVS (0) and VKTX (0) have equivalent revenues.
CRVSVKTXCRVS / VKTX
Capitalization249M2.88B9%
EBITDA-25M-150.58M17%
Gain YTD-31.589-36.23387%
P/E RatioN/AN/A-
Revenue00-
Total Cash41.7M903M5%
Total Debt354K1.12M32%
FUNDAMENTALS RATINGS
CRVS vs VKTX: Fundamental Ratings
CRVS
VKTX
OUTLOOK RATING
1..100
2311
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
45
Fair valued
PROFIT vs RISK RATING
1..100
7972
SMR RATING
1..100
9742
PRICE GROWTH RATING
1..100
6191
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
8549

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VKTX's Valuation (45) in the Biotechnology industry is in the same range as CRVS (72) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew similarly to CRVS’s over the last 12 months.

VKTX's Profit vs Risk Rating (72) in the Biotechnology industry is in the same range as CRVS (79) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew similarly to CRVS’s over the last 12 months.

VKTX's SMR Rating (42) in the Biotechnology industry is somewhat better than the same rating for CRVS (97) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew somewhat faster than CRVS’s over the last 12 months.

CRVS's Price Growth Rating (61) in the Pharmaceuticals Major industry is in the same range as VKTX (91) in the Biotechnology industry. This means that CRVS’s stock grew similarly to VKTX’s over the last 12 months.

CRVS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as VKTX (100) in the Biotechnology industry. This means that CRVS’s stock grew similarly to VKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSVKTX
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 22 days ago
90%
Bearish Trend 18 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
70%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RSQCX11.960.17
+1.44%
Royce Small-Cap Special Equity Consult
JDSCX28.86N/A
N/A
JPMorgan Small Cap Blend I
SCSIX35.32N/A
N/A
Sterling Capital SmCp Val R6
AHGCX8.83N/A
N/A
American Century Heritage C
CGLAX15.69N/A
N/A
Calvert Global Equity Fund Class A

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
+3.98%
SYRE - CRVS
36%
Loosely correlated
+4.99%
VRDN - CRVS
36%
Loosely correlated
+0.37%
CRSP - CRVS
34%
Loosely correlated
+1.48%
VKTX - CRVS
34%
Loosely correlated
-0.50%
FULC - CRVS
34%
Loosely correlated
-2.23%
More